Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.

The science of drug metabolism and pharmacokinetics (DMPK) has developed significantly over the past 20 years, and its functional role in today's pharmaceutical industry has matured to the point where DMPK has become an indispensable discipline in support of drug discovery and development. While contributions to the lead optimization phase of discovery efforts have been particularly noteworthy in helping to select only the best drug candidates for entry into development, it should be recognized that the scope of DMPK spans the continuum of discovery through clinical evaluation and even into the post-marketing phase; as such, the breadth of DMPK's involvement is almost unique in contemporary pharmaceutical research. This perspective summarizes notable advances in the field, many of which have been made possible by technological developments in areas such as molecular biology, genetics, and bioanalytical chemistry, and highlights the critical nature of key partnerships between Drug Metabolism, Medicinal Chemistry, and Safety Assessment groups in attempting to advance drug candidates with a low potential for causing adverse events in humans. Finally, some speculative predictions are made of the future role of DMPK in pharmaceutical research, where current advances in our mechanistic understanding of the molecular processes that control the absorption, disposition, metabolism, elimination, and toxicity of drugs and their biotransformation products will combine to further enhance the impact of DMPK in drug discovery and development.

[1]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[2]  T. Baillie,et al.  Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. , 2006, Chemical research in toxicology.

[3]  Jing Lin,et al.  The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. , 2003, Current topics in medicinal chemistry.

[4]  B. Corrigan,et al.  How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  T. Baillie,et al.  Organic Chemistry in Drug Discovery , 2004, Science.

[6]  Thomayant Prueksaritanont,et al.  Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. , 2006, Toxicology and applied pharmacology.

[7]  Dominic P. Williams,et al.  Toxicophores: investigations in drug safety. , 2006, Toxicology.

[8]  Desmond O'Connor,et al.  Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. , 2005, Rapid communications in mass spectrometry : RCM.

[9]  Dominic P. Williams,et al.  Selection of new chemical entities with decreased potential for adverse drug reactions. , 2006, European journal of pharmacology.

[10]  A. Seeringer,et al.  Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.

[11]  R Scott Obach,et al.  Metabolites and safety: What are the concerns, and how should we address them? , 2006, Chemical research in toxicology.

[12]  Dominic P. Williams,et al.  Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.

[13]  J. Uetrecht,et al.  Idiosyncratic drug reactions: current understanding. , 2007, Annual review of pharmacology and toxicology.

[14]  T. Baillie,et al.  Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. , 2004, Analytical chemistry.

[15]  F. Guengerich,et al.  Untargeted analysis of mass spectrometry data for elucidation of metabolites and function of enzymes. , 2007, Analytical chemistry.

[16]  L. Benet,et al.  IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY , 2006, Drug Metabolism and Disposition.

[17]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[18]  Albert P. Li,et al.  A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. , 2002, Chemico-biological interactions.

[19]  Jiunn H Lin,et al.  Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. , 2007, Current drug metabolism.

[20]  L. Chinn,et al.  ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.

[21]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[22]  Bradley L Urquhart,et al.  Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.

[23]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  T. Yokoi,et al.  Application of Chimeric Mice with Humanized Liver for Predictive ADME , 2007, Drug metabolism reviews.

[25]  B. Warrack,et al.  Utility of the hybrid LTQ-FTMS for drug metabolism applications. , 2006, Current drug metabolism.

[26]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[27]  M. Hutzler,et al.  Predicting drug-drug interactions in drug discovery: where are we now and where are we going? , 2005, Current opinion in drug discovery & development.

[28]  Michael McMillian,et al.  Application of genomics in preclinical drug safety evaluation. , 2006, Basic & clinical pharmacology & toxicology.

[29]  M. Beconi,et al.  A semi-automated method for measuring the potential for protein covalent binding in drug discovery. , 2005, Journal of pharmacological and toxicological methods.

[30]  A. Y. Lu,et al.  Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective. , 2005, Current drug metabolism.

[31]  D. Liebler,et al.  Protein targets of reactive electrophiles in human liver microsomes. , 2007, Chemical research in toxicology.

[32]  Ulf Norinder,et al.  Prediction of ADMET Properties , 2006, ChemMedChem.

[33]  J. Brockmöller,et al.  Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs , 2005, Clinical pharmacokinetics.

[34]  R. Snyder,et al.  Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. , 2006, Pharmacogenomics.

[35]  James L Stevens,et al.  Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here? , 2006, Chemical research in toxicology.

[36]  W. Evans Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy , 2004, Therapeutic drug monitoring.

[37]  R. Weinshilboum,et al.  Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.

[38]  Michelle L. Reyzer,et al.  MALDI-MS-based imaging of small molecules and proteins in tissues. , 2007, Current Opinion in Chemical Biology.

[39]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[40]  J. Woodcock,et al.  The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.

[41]  Leslie Z Benet,et al.  Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems , 2006, Journal of Pharmacology and Experimental Therapeutics.

[42]  Karen L Davis-Bruno,et al.  A regulatory perspective on issues and approaches in characterizing human metabolites. , 2006, Chemical research in toxicology.

[43]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[44]  W Griffith Humphreys,et al.  Safety assessment of drug metabolites: Characterization of chemically stable metabolites. , 2006, Chemical research in toxicology.

[45]  M. Fielden,et al.  The state-of-the-art in predictive toxicogenomics. , 2006, Current opinion in drug discovery & development.

[46]  R. Aebersold,et al.  Mass Spectrometry and Protein Analysis , 2006, Science.

[47]  A. D. Rodrigues,et al.  Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. , 2002, Current drug metabolism.

[48]  T. Baillie,et al.  Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.

[49]  A. Nassar,et al.  Strategies for dealing with reactive intermediates in drug discovery and development. , 2004, Current opinion in drug discovery & development.

[50]  J. Bolton,et al.  Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study. , 2005, Chemical research in toxicology.

[51]  F. Guengerich,et al.  Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.

[52]  J. Waring,et al.  Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. , 2005, Current opinion in drug discovery & development.

[53]  N. Risch,et al.  Functional genomics of membrane transporters in human populations. , 2005, Genome research.

[54]  R. Cooks,et al.  Ambient Mass Spectrometry , 2006, Science.

[55]  F Peter Guengerich,et al.  Applying mechanisms of chemical toxicity to predict drug safety. , 2007, Chemical research in toxicology.

[56]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[57]  Karen Brown,et al.  Applications of accelerator mass spectrometry for pharmacological and toxicological research. , 2006, Mass spectrometry reviews.

[58]  H. Greenberg,et al.  American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process , 2007, Journal of clinical pharmacology.